Related Experiment Videos
[Interleukin-2 in the treatment of malignant melanoma. A case report]
C Szczylik1, J Knap, A Badowski
1Zakładu Immunologii CSK WAM.
Polskie Archiwum Medycyny Wewnetrznej
|November 1, 1990
Abstract:
Interleukin-2 is a lymphokine with documented antineoplastic influence, with not completely understood mechanism of action. The case of 46-years old patient with relapsed metastatic malignant melanoma treated with constant-infusion of rIL-2 is described. 9-month remission was achieved. During the course of treatment a lot of side effects including flu-like symptoms, hypotonia, anemia and thrombocytopenia, and also many biochemical disturbances were observed.